Results 91 to 100 of about 75,344 (257)

Somatostatin receptor imaging. the presence of somatostatin receptors in rheumatoid arthritis [PDF]

Arthritis & Rheumatism, 1994
AbstractObjective. To investigate the in vivo and in vitro expression of somatostatin receptors (SS‐R) on synovial membranes of patients with rheumatoid arthritis (RA).Methods. The joints of 14 consecutive patients with active RA, 4 patients with severe osteoarthritis (OA), and 30 control patients were studied.
P M, Vanhagen, H M, Markusse, S W, Lamberts, D J, Kwekkeboom, J C, Reubi, E P, Krenning   +5 more
openaire   +2 more sources

Exocrine Gland Dysfunction in Parkinson's Disease: Pathophysiology, Clinical Manifestations, and Therapeutic Perspectives—A Narrative Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Non‐motor symptoms, especially autonomic dysfunction, are major contributors to disability and decreased quality of life in Parkinson's disease (PD). Despite being common and having a wide range of clinical facets, exocrine gland dysfunction is still not well recognized and managed.
Renato P. Munhoz, Marina Farah, Laura Silveira‐Moriyama   +2 more
wiley   +1 more source

Review of nutrition management of pediatric intestinal pseudo‐obstruction

Nutrition in Clinical Practice, EarlyView.
Abstract Chronic intestinal pseudo‐obstruction (CIPO) is a rare, heterogeneous, and debilitating disorder characterized by profound intestinal dysmotility and severe nutrition challenges. Its presentation resembles that of mechanical bowel obstruction, but CIPO occurs in the absence of luminal obstruction.
Senthilkumar Sankararaman, Raisa Rani James, Bushra El‐Amaireh, Andrea Adler, Kadakkal Radhakrishnan, Sujithra Velayuthan   +5 more
wiley   +1 more source

Current Cell/Organoid and Animal Models for Primary Sclerosing Cholangitis

Portal Hypertension &Cirrhosis, EarlyView.
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease with limited therapeutic options and a marked risk of progression to biliary fibrosis, cirrhosis, and malignancy. Progress in PSC research has been hindered by the lack of models that faithfully recapitulate the complex biliary microenvironment and disease heterogeneity ...
Qigu Yao, Sheng Cheng, Qiaoling Pan, Jiong Yu, Hongcui Cao   +4 more
wiley   +1 more source

Boron‐10 carriers and their applications in boron neutron capture therapy

Precision Radiation Oncology, EarlyView.
Summary of different types of boron drugs. Abstract Boron neutron capture therapy (BNCT) has emerged as a promising therapeutic modality in cancer treatment, demonstrating the ability to selectively eliminate cancer cells through the 10B(n,α)7Li nuclear reaction with minimal side effects on normal tissues.
Dachao Tang, Mengqi Shi, Zhichen Mao, Weiya Chen, Xiaoling Li, Xiao Yan Zhao, Zhigang Liu, Xiao Xu   +7 more
wiley   +1 more source

Treatment challenges in and outside a specialist network setting: Pancreatic neuroendocrine tumours [PDF]

, 2019
Pancreatic Neuroendocrine Neoplasms comprise a group of rare tumours with special biology, an often indolent behaviour and particular diagnostic and therapeutic requirements.
Almar E., Arveux P., Autelitano M., Baldi I., Bara S., Barchielli A., Benfatto L., Benhamou E., Bento M. J., Bielska-Lasota M., Blaszczyk J., Bordoni A., Botta L., Bouchardy C., Bouvier A. -M., Bouvier V., Brewster D. H., Calleja N., Candela P., Caplin M., Capocaccia R., Carulla M., Clough-Gorr K., Colonna M., Comber H., De Angelis R., de Lacerda G. F., de Munain A. L., Diaz Garcia J. M., Diba C. S., Dimitrova N., Dusek L., Engel J., Ess S. M., Falcini F., Falconi M., Ferretti S., Filiberti R. A., Fusai G. K., Fusco M., Galceran J., Gatta G., Gavin A., Gennaro V., Gentilini M., Giacomin A., Gozdz S., Grosclaude P., Guizard A. -V., Hackl M., Heidrich J., Henau K., Holleczek B., Huws D. W., Iannelli A., Johannesen T. B., Jonasson J. G., Kepska K., Knijn A., Konzelmann I., Kunkler I., Lapotre-Ledoux B., Larranaga N., Leinonen M., Luttmann S., Lykoudis P. M., Madeddu A., Magi M., Malila N., Mallone S., Mangone L., Marani E., Marcos-Gragera R., Maspero S., Maynadie M., Mazzoleni G., Michiara M., Miranda A., Molinie F., Monnereau A., Moreno-Iribas C., Mousavi M., Muffatti F., Navarro C., Nennecke A., Pannozzo F., Partelli S., Pierannunzio D., Piffer S., Pildava S., Primic-Zakelj M., Rachtan J., Rashbass J., Ricci P., Robaszkiewicz M., Rossi S., Rugge M., Salmeron D., Sanchez M. J., Santaquilani M., Sardo A. S., Schubert-Fritschle G., Schvartz C., Sekerija M., Sensi F., Serraino D., Smailyte G., Spagnoli G., Stabenow R., Stracci F., Tagliabue G., Tavilla A., Torrella-Ramos A., Trama A., Tretarre B., Troussard X., Tumino R., Usala M., Van Eycken E., Velten M., Visser O., Vitale F., Woronoff A. -S., Ziino A.   +123 more
core   +1 more source

SSTR1 and SSTR5 subtypes are the dominant forms of somatostatin receptor in neuroendocrine tumors.

Folia Histochemica et Cytobiologica, 2010
The effectiveness of the long acting somatostatin analogues like octreotide and lanreotide depends on the expression of specific somatostatin receptors on the target cells.
Jolanta Kunert-Radek, Marek Pawlikowski, Hanna Pisarek, Robert Kubiak, Katarzyna Winczyk   +4 more
doaj   +1 more source

Pancreatic tumors imaging: an update [PDF]

, 2016
Currently, ultrasound (US), computed tomography (CT) and Magnetic Resonance imaging (MRI) represent the mainstay in the evaluation of pancreatic solid and cystic tumors affecting pancreas in 80-85% and 10-15% of the cases respectively. Integration of US,
Baccari, Paolo, Cappabianca, Salvatore, D'Andrea, Alfredo, Falcone, Giuseppe, Gravante, Sabrina, Manganaro, Lucia, Palumbo, Barbara, Reginelli, Alfonso, Scialpi, Michele   +8 more
core   +1 more source

Psilocybin as a novel treatment for chronic pain

British Journal of Pharmacology, EarlyView.
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey, Reena Lasrado, Maria Maiarú, Gary J. Stephens   +3 more
wiley   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source